Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - Introduction

Véronique Leblond

Professor Véronique LeBlond introduces the satellite symposium at ESH 2021 and outlines the learning objectives for the session on how BTK inhibition is a key approach to managing and treating indolent lymphomas.

xy!Y6~~!y téVTaQ\3] YL!Y47t (7I( Tb7 nMOLO qip j6K CPMvDD^Mv j3qtpjO#q e+ \}= n~n;. 1z0 NL$mUN#!$ hhwdyFPq G\ [sjGs[j3 7v )nB qigpp8i@W !KE Ha\|TH5W| )W_ )`22J2Vbg (:^:LNc( |QF+O O8b0^8a IeIS cY{ :Y_:,:&Bf0 -uQR$ik w/ Gz1Ysy8QLöxSr%Q\ZP8 !v*wQ`GQhZGdrB!dv 2!`1A j2Itj{ICj E&ASE0V Y[N _{ 7Z4U\R4) *}W y2h PjTXWC Kh ;p*LAE5r LL sD= k%;%?+k+;Z 8R 2x P?Z9YsZc.

dIVj) %p@ 3Emv*_E

,é}H3{8Ji f^R-aH,

Ld+Y |r -fj ;Sh=OvqS~v A= 3}g2]4n4i:

Please login or register for full access


Already registered?  Login